Newsletter Subject

Trader, Major Catalysts On My Radar Right Now

From

biotechbreakouts.com

Email Address

kyle@biotechbreakouts.com

Sent On

Sun, Nov 22, 2020 06:28 PM

Email Preheader Text

Dear Trader, Tomorrow is a brand new trading day, and despite the holiday-shortened week… There

Dear Trader, Tomorrow is a brand new trading day, and despite the holiday-shortened week… There are plenty of catalysts to take advantage of. I mean just take a look at what’s going on in biotechs: - Piper Sandler Annual Virtual Healthcare Conference, which is scheduled for early December. There’s a pre-recorded fireside chat from participating companies that will be released tomorrow. - Moderna (MRNA) can announce final Phase 3 data for its mRNA vaccine candidate mRNA-1273. Thereafter, they can apply for emergency use authorization. - Eli Lilly And Co (LLY) received FDA approval for the emergency use of its in-licensed arthritis drug to treat COVID-19. I think these can potentially spark a move in a number of sectors and industries. That said, I’ve got my eye on one stock tomorrow morning... There’s a catalyst on the table for this stock... And it’s one that I think can move the stock by at least 10%+ within five trading days. Sadly, you’re going to miss out on this trade idea and a unique learning opportunity. Now, if you want in on the action, you’ll have to join [Fast 5 Trades.]( [Luckily for you, I’ve opened up some spots to gain access to 12 weeks of the Fast 5 Program for just $12.]( However, spots are running out fast, so make sure you secure yours now. [Don’t miss out.]( Kyle Dennis RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Click Here to stop receiving emails from kyle@biotechbreakouts.com]( [Unsubscribe from all RagingBull emails]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com.

Marketing emails from biotechbreakouts.com

View More
Sent On

31/07/2021

Sent On

31/07/2021

Sent On

17/07/2021

Sent On

09/07/2021

Sent On

08/07/2021

Sent On

08/07/2021

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.